

**Faron Pharmaceuticals Oy**  
("Faron" or the "Company")

**Faron Pharmaceuticals to Participate in Upcoming Investor Conferences**

**TURKU – FINLAND, 23 November 2020** – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announced that management will participate in the following virtual investor conferences:

- **32nd Annual Piper Sandler Virtual Healthcare Conference**  
Pre-recorded fireside chat available on-demand starting Monday, 23 November 2020 at 10:00 a.m. ET
- **3rd Annual Evercore ISI HealthCONx Conference**  
Fireside Chat on Wednesday, 2 December 2020 at 8:25 a.m. ET

Audio webcasts of the presentations will be available in the "Investors" section on Faron's website at <https://www.faron.com/investors>

**ENDS**

**For more information please contact:**

**Stern Investor Relations, Inc.**

Julie Seidel, Naina Zaman  
Phone: +(1)212 362 1200  
Email: [faron@sternir.com](mailto:faron@sternir.com)

**Consilium Strategic Communications**

Mary-Jane Elliott, David Daley, Lindsey Neville  
Phone: +44 (0)20 3709 5700  
E-mail: [faron@consilium-comms.com](mailto:faron@consilium-comms.com)

**About Faron Pharmaceuticals Ltd**

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (*bexmarilimab*), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel

macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures is currently being tested in several Phase III studies around the world against COVID-19. Traumakine is intravenous IFN beta-1a, which is a strong anti-viral and anti-inflammatory agent. Faron is based in Turku, Finland. Further information is available at [www.faron.com](http://www.faron.com)